牛牛AI助手已提取核心信息
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced on March 4, 2024, the appointment of Dr. Ramiro Ribeiro as its new Chief Medical Officer, effective March 1, 2024. Dr. Ribeiro, a trained retinal specialist, succeeds Dr. Dario Paggiarino, who has served in the role since 2016 and will depart the company on March 31, 2024. Dr. Ribeiro's previous experience includes serving as Vice President, Head of Clinical Development at Apellis Pharmaceuticals, where he led the global Phase 3 clinical program in Geographic Atrophy. EyePoint Pharmaceuticals is preparing for the upcoming Phase 2 PAVIA trial results of EYP-1901 for NPDR in Q2 2024 and the initiation of the Phase 3 LUGANO trial in wet AMD in the second half of the year. The company's pipeline leverages its proprietary Durasert E™ technology for sustained intraocular drug delivery, with EYP-1901 being a leading product candidate. The announcement also included the grant of stock options to Dr. Ribeiro as an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4).
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced on March 4, 2024, the appointment of Dr. Ramiro Ribeiro as its new Chief Medical Officer, effective March 1, 2024. Dr. Ribeiro, a trained retinal specialist, succeeds Dr. Dario Paggiarino, who has served in the role since 2016 and will depart the company on March 31, 2024. Dr. Ribeiro's previous experience includes serving as Vice President, Head of Clinical Development at Apellis Pharmaceuticals, where he led the global Phase 3 clinical program in Geographic Atrophy. EyePoint Pharmaceuticals is preparing for the upcoming Phase 2 PAVIA trial results of EYP-1901 for NPDR in Q2 2024 and the initiation of the Phase 3 LUGANO trial in wet AMD in the second half of the year. The company's pipeline leverages its proprietary Durasert E™ technology for sustained intraocular drug delivery, with EYP-1901 being a leading product candidate. The announcement also included the grant of stock options to Dr. Ribeiro as an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4).
处于临床阶段的生物制药公司EyePoint Pharmicals, Inc. 于2024年3月4日宣布，任命拉米罗·里贝罗博士为新任首席医学官，自2024年3月1日起生效。里贝罗博士是一位训练有素的视网膜专家，他接替了达里奥·帕贾里诺博士。达里奥·帕贾里诺博士自2016年以来一直担任该职务，并将于2024年3月31日离开公司。里贝罗博士之前的经历包括在Apellis Pharmicals担任副总裁兼临床开发主管，在那里他领导了《地理萎缩》的全球三期临床项目。EyePoint Pharmaceuticals 正在为即将于 2024 年第二季度发布的 NPDR EYP-1901 第二阶段 PAVI...展开全部
处于临床阶段的生物制药公司EyePoint Pharmicals, Inc. 于2024年3月4日宣布，任命拉米罗·里贝罗博士为新任首席医学官，自2024年3月1日起生效。里贝罗博士是一位训练有素的视网膜专家，他接替了达里奥·帕贾里诺博士。达里奥·帕贾里诺博士自2016年以来一直担任该职务，并将于2024年3月31日离开公司。里贝罗博士之前的经历包括在Apellis Pharmicals担任副总裁兼临床开发主管，在那里他领导了《地理萎缩》的全球三期临床项目。EyePoint Pharmaceuticals 正在为即将于 2024 年第二季度发布的 NPDR EYP-1901 第二阶段 PAVIA 试验结果以及下半年在湿性 AMD 中启动的 3 期 LUGANO 试验做准备。该公司的产品线利用其专有的 Durasert E™ 技术实现持续的眼内药物输送，其中 EYP-1901 是领先的候选产品。该公告还包括根据纳斯达克上市规则5635（c）（4）向里贝罗博士授予股票期权作为激励奖励。
有用
没用